medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

CIRCCVG/2022/003704/R2

Prevalence and disease expression of pathogenic and likely pathogenic variants associated with inherited cardiomyopathies in the general population

Mimount Bourfiss, MD[1]*; Marion van Vugt, MSc[1]*; Abdulrahman I. Alasiri, MSc[1]; Bram Ruijsink, MD, PhD[1,2]; Jessica van Setten, MSc, PhD[1]; Amand F. Schmidt, MSc, PhD[1,3] ; Dennis Dooijes, PhD[4]; Esther Puyol-Antón, PhD[2]; Birgitta K. Velthuis, MD, PhD[5]; J. Peter van Tintelen, MD, PhD[4]; Anneline S.J.M. te Riele, MD, PhD[1,6]; Annette F. Baas, MD, PhD[4]; Folkert W. Asselbergs, MD, PhD[1,3,7].

*Shared first authorship

Affiliations

1. Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
2. School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom
3. Institute of Cardiovascular Science, London, Faculty of Population Health Sciences, University College London, United Kingdom
4. Department of Genetics, University Medical Center Utrecht, Utrecht, Utrecht University, Utrecht, the Netherlands
5. Department of Radiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
6. Netherlands Heart Institute, Utrecht, the Netherlands
7. Health Data Research UK and Institute of Health Informatics, University College London, London, United Kingdom

Short title: Cardiomyopathy variants in the general population

Corresponding author: Mimount Bourfiss; Department of Medicine, Division of Cardiology; University Medical Center Utrecht; room E.02.561; Heidelberglaan 100; 3584 CX Utrecht, the Netherlands. Email address: m.bourfiss-2@umcutrecht.nl Telephone number: +31-88-77570240. Fax number: +31-88-7555660.

Journal Subjects Terms: Cardiomyopathy, Genetics, Heart failure, Hypertrophy, Magnetic Resonance imaging

Total word count: 6993

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Abstract

Background. Pathogenic and likely pathogenic variants associated with arrhythmogenic right ventricular cardiomyopathy (ARVC), dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) are recommended to be reported as secondary findings in genome sequencing studies. This provides opportunities for early diagnosis, but also fuels uncertainty in variant carriers (G+), since disease penetrance is incomplete. We assessed the prevalence and disease expression of G+ in the general population.

Methods. We identified pathogenic and likely pathogenic variants associated with ARVC, DCM and/or HCM in 200,643 UK Biobank individuals, who underwent whole exome sequencing. We calculated the prevalence of G+ and analysed the frequency of cardiomyopathy/heart failure diagnosis. In undiagnosed individuals, we analysed early signs of disease expression using available electrocardiography and cardiac magnetic resonance imaging data.

Results. We found a prevalence of 1:578, 1:251 and 1:149 for pathogenic and likely pathogenic variants associated with ARVC, DCM and HCM respectively. Compared to controls, cardiovascular mortality was higher in DCM G+ (OR 1.67 [95% CI 1.04;2.59], p=0.030), but similar in ARVC and HCM G+ ($p \geq 0.100$). Cardiomyopathy or heart failure diagnosis were more frequent in DCM G+ (OR 3.66 [95% CI 2.24;5.81], $p=4.9\times10^{-7}$) and HCM G+ (OR 3.03 [95% CI 1.98;4.56], $p=5.8\times10^{-7}$), but comparable in ARVC G+ (p=0.172). In contrast, ARVC G+ had more ventricular arrhythmias ($p=3.3\times10^{-4}$). In undiagnosed individuals, left ventricular ejection fraction was reduced in DCM G+ (p=0.009).

Conclusions. In the general population, pathogenic and likely pathogenic variants associated with ARVC, DCM or HCM are not uncommon. Although G+ have increased mortality and morbidity, disease penetrance in these carriers from the general population remains low

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

(1.2-3.1%). Follow-up decisions in case of incidental findings should not be based solely on a variant, but on multiple factors, including family history and disease expression.

Key Words: whole exome sequencing, genetics, arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy

Non-standard Abbreviations and Acronyms

ACMG – American College of Medical Genetics and Genomics

ACTC1 – Actin Alpha Cardiac Muscle 1

ACTN1 – Alpha-actinin 2

AHA – American Heart Association

ARVC – Arrhythmogenic right ventricular cardiomyopathy

BAG3 – BAG Cochaperone 3

BMI – Body mass index

CI – Confidence interval

ClinGen – Clinical Genome Resource

CMR – Cardiac magnetic resonance imaging

CSRP3 – Cysteine And Glycine Rich Protein 3

DCM – Dilated cardiomyopathy

DES – Desmin

DSC2 – Desmocollin 2

DSG2 – Desmoglein 2

DSP – Desmoplakin

ECG – Electrocardiography

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

EDM – End diastolic mass

EDV – End diastolic volume

EF – Ejection fraction

ESV – End systolic volume

FLNC – Filamin-C

G+ – Genotype positive (variant carriers)

G- – Genotype negative (controls)

i – Indexed, corrected for body surface area

JPH2 – Junctophilin 2

JUP – Junction Plakoglobin

HCM – Hypertrophic cardiomyopathy

LMNA – Lamin A/C

LoF – Loss of function

LV – Left ventricular

MAF – Minor allele frequency

MET – Metabolic equivalent of task minutes

MVR – Mass to EDV ratio

MYBPC3 – Myosin Binding Protein C3

MYH7 – Myosin Heavy Chain 7

MYL2 – Myosin Light Chain 2

MYL3 – Myosin Light Chain 3

NEXN – Nexilin F-Actin Binding Protein

NGS – Next generation sequencing

OR – Odds ratio

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

P+ – Phenotype positive

P- – Phenotype negative

PKP2 – Plakophilin 2

PLN – Phospholamban

RBM20 – RNA Binding Motif Protein 20

RV – Right ventricular

SCN5A – Sodium Voltage-Gated Channel Alpha Subunit 5

SD – Standard deviation

SV – Stroke volume

TFC – Task force criteria

TMEM43 – Transmembrane Protein 43

TNNC1 – Troponin C1, Slow Skeletal And Cardiac Type

TNNI3 – Troponin I3, Cardiac Type

TNNT2 – Troponin T2, Cardiac Type

TPM1 – Tropomyosin 1

TTN – Titin

UKB – UK Biobank

VKGL – Vereniging Klinische Genetische Laboratoriumdiagnostiek

VCL – Vinculin

WES – Whole exome sequencing

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Background

The major inherited cardiomyopathies arrhythmogenic right ventricular cardiomyopathy (ARVC), dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) are characterized by ventricular dysfunction and ventricular arrhythmias that can lead to progressive heart failure and sudden cardiac death[1]. ARVC is mainly caused by pathogenic variants in desmosomal genes, whereas DCM and HCM are mainly caused by sarcomeric gene variants[2]. These cardiomyopathies are typically inherited in an autosomal dominant fashion with incomplete penetrance and variable expressivity. As such, phenotypic expression may vary greatly, even among family members or individuals carrying the same pathogenic variant.

With the implementation of next-generation sequencing (NGS), genetic testing has become an important part of routine clinical care in the diagnosis of inherited cardiomyopathies[3]. Technical advances and commercial availability of NGS, have led to more affordable and accessible genetic testing. The American College of Medical Genetics and Genomics (ACMG) has developed recommendations for the reporting of incidental or secondary findings unrelated to the test indication[4]. In this framework, variants in genes associated with ARVC, DCM and HCM are recommended to be reported as secondary findings from clinical exome and other genome sequencing tests[4]. Although this offers the potential to prevent morbidity and mortality of heart failure and sudden cardiac death by early treatment, it also fuels uncertainty in carriers of likely pathogenic or pathogenic variants (G+) and their family members, since factors that influence disease penetrance in the general population are largely unknown. More knowledge about disease penetrance of these variants in an unselected population cohort is needed to determine screening protocols in these individuals.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

In this study, we aimed to assess the prevalence of pathogenic and likely pathogenic variants in the general population using a set of recently curated genes for ARVC[5], DCM[6] and HCM[7] in two (inter)national databases[8] (see **Figure 1** and **Table I**). In order to do so, we leveraged data from the UK Biobank (UKB), a population-based cohort with whole exome sequencing (WES) data available of 200,643 individuals[9]. Furthermore, we looked into the UKB-reported phenotypical characteristics of these G+ and assessed the occurrence of early signs of disease in undiagnosed G+ using available electrocardiography and cardiac magnetic resonance (CMR) imaging data.

Methods

Ethics approval for the UKB study was obtained from the North West Centre for Research Ethics Committee (11/NW/0382) and all participants provided informed consent. All data and materials have been made publicly available on Github and can be accessed at https://github.com/CirculatoryHealth/Inherited-cardiomyopathies. Full methods are available in the **Supplemental Material**. Disease definitions are given in **Table II**.

Results

Population characteristics

We identified 2,207/200,643 unique G+ individuals from a total of 2,493 included individuals (89%) (see **Figure 2**) classified as 1) ARVC G+ (n=347, 54% female, median age of 57 [50-64] years); 2) DCM G+ (n=800, 56% female, median age of 58 [51-64] years) and; 3) HCM G+ (n=1,346, 54% female, median age of 56 [49-63] years). The matched control group consisted of 9,972 individuals (55% females, median age of 57 [49-63] years). **Table 1** and **Table III** show the baseline characteristics of the included individuals. The majority of G+

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

were of white ethnicity (ARVC 90%, DCM 96%, HCM 75%), followed by Asian (ARVC 3%, DCM 1%, HCM 19%) and black ethnicity (ARVC 2%, DCM 2% and HCM 2%). This is comparable to what is observed in the UKB, where the majority is of white ethnicity (94%), followed by Asian (2%) and black ethnicity (2%).

Genotypic characteristics of pathogenic and likely pathogenic variant carriers

Prevalence of pathogenic and likely pathogenic variants in the general population

We found a prevalence of 1 ARVC G+ in 578 people in the general population (1:578 [1:521; 1:644]) and identified 75 variants out of the 593 (13%) pathogenic and likely pathogenic variants described in ClinVar and VKGL: 13 missense and 62 loss of function (LoF) (**Table IV**). As shown in **Figure 3**, most ARVC G+ harbored a pathogenic variant in *PKP2* (n=185, 53%), followed by *DSP* (n=49, 14%), *DSC2* (n=42, 12%), *DSG2* (n=31, 9%), *JUP* (n=24, 7%), *DES* (n=15, 4%), and *PLN* (n=1, 0.3%).

We found a prevalence of 1:251 [1:234; 1:269] DCM G+ and identified 216 out of 3,460 (6%) pathogenic and likely pathogenic variants described in ClinVar and VKGL: 80 missense and 136 LoF (**Table IV**). Variants in *TTN* (n=272, 34%) and *MYH7* (n=158, 20%) were most prevalent among DCM G+, followed by *SCN5A* (n=59, 7%), *FLNC* (n=56, 7%), *DSP* (n=49, 6%), *DES* (n=49, 6%), *LMNA* (n=42, 5%), *TNNI3* (n=35, 4%) and *TNNT2* (n=32, 4%). Eight more genes with a frequency of less than 3% were identified: *BAG3*, *PLN*, *TNNC1, ACTN2*, *RBM20, NEXN, TPM1,* and *ACTC1* (**Figure 3**).

We found a prevalence of 1:149 [1:141; 1:157] HCM G+ and identified 131 out of 1,512 (9%) pathogenic and likely pathogenic variants from ClinVar and VKGL: 98 missense and 23 LoF (**Table IV**). Most individuals carried a pathogenic and likely pathogenic variant in *MYBPC3* (n=723, 54%), followed by *TNNT2* (n=274, 20%), *MYH7* (n=232, 17%), and *TNNI3*

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

(n=50, 4%). A frequency of less than 3% was found in *CSRP3, MYL2, TNNC1, JPH2, TPM1, ACTC1,* and *MYL3* (**Figure 3**). Interestingly, a variant in *TNNT2* (c.862C>T p.Arg288Cys) affected 242 individuals (18%). Four of these carriers were diagnosed with heart failure, of whom one also with HCM. All four heart failure patients also suffered from chronic ischemic heart disease. Furthermore, a variant in *MYBPC3* (c.3628-41_3628-17del) was mainly seen in individuals with an Asian ethnicity (n=237, 18% of the total HCM G+). Four of these individuals were diagnosed with heart failure, of whom two also had coronary artery disease and one was diagnosed with DCM, however none were diagnosed with HCM. When excluding these two variants, we found a HCM G+ prevalence of 1:250 [1:234; 1:269]. *MYBPC3* remained the most prevalent gene (52%), whereas the *TNNT2* frequency decreased to 4%.

The prevalence of G+ per gene for all cardiomyopathies is depicted in **Table V**.

<u>Overlapping variants and individuals</u>

Some pathogenic and likely pathogenic variants were identified in multiple cardiomyopathy subtypes. First, 26 variants were described in both ARVC and DCM, affecting 53 individuals. Most of these variants (n=20/26 variants, 77%) were found in *DSP* (n=37 individuals, 70%), of whom one individual (3%) had heart failure and one (3%) was diagnosed with a cardiomyopathy. Five variants out of 26 (19%) were found in *DES* (n=15 individuals, 28%) of whom two individuals (13%) had heart failure, and one was diagnosed with both DCM and HCM. One variant out of 26 (4%) was found in *PLN* (c.26G>A; p.Arg9His, NM_002667.5) in one individual (2%) who was not diagnosed with a cardiomyopathy or heart failure.

Second, 52 variants were described in DCM and HCM, affecting 232 individuals. Most of these variants (n=33/52 variants, 63%) were found in *MYH7* (n=158 individuals, 68%),

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

followed by 10 variants (19%) in *TNNT2* (n=29 individuals, 13%), 6 variants (12%) in *TNNI3* (n=35 individuals, 15%), and 1 (2%) variant in *TNNC1*, *ACTC1* as well as *TPM1*. In this group of 232 individuals, 9 (4%) individuals had a cardiomyopathy or heart failure diagnosis, of whom 5 were diagnosed with HCM and none with DCM.

Furthermore, three individuals carried two pathogenic variants. Individual 1 was a 65-year old male, carrying variants in *MYBPC3* (c.3628-41_3628-17del, NM_000256.3) and *TNNT2* (c.460C>T; p.Arg154Trp, NM_001276345.2) and was diagnosed with heart failure, with underlying chronic ischemic heart disease. Individual 2 was a 65-year old male, carrying variants in *FLNC* (c.7450G>A; p.Gly2484Ser, NM_001458.5) and *PKP2* (c.1867G>T; p.Glu623Ter, NM_001005242.3) and was therefore included in both the ARVC as well as the DCM G+ group. Individual 3 was a 64-year old male, carrying variants in *MYBPC3* (c.1504C>T; p.Arg502Trp, NM_000256.3) and *MYH7* (c.5655G>A; p.Ala1885=, NM_000257.4). Individuals 2 and 3 were not diagnosed with a cardiomyopathy or heart failure and none had CMR data available.

Table VI shows the prevalence of the cardiomyopathy variants, with and without the inclusion of overlapping variants.

Phenotypic characteristics of pathogenic and likely pathogenic variant carriers

<u>Cardiovascular risk factors</u>

Hypertension, BMI, and level of activity in metabolic equivalent of task minutes (MET) per week were comparable between G- and G+ for all cardiomyopathies (p≥0.055; **Table 1** and **Table VII**). Diabetes was more prevalent in G+ HCM (9.2% (G-) vs 11.4% (G+), p=0.008), while smoking was more prevalent in DCM G+ (41.4% vs 46.4%, p=0.007) (**Table VIII**).

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Cardiovascular disease

As seen in **Figure 4** and **Table VIII**, compared to G-, cardiomyopathy/heart failure without previous ischemic heart disease (P+, phenotype positive) was more often diagnosed in DCM G+ (OR 3.66 [95% CI 2.24;5.81], $p=4.9\times10^{-7}$) and HCM G+ (OR 3.03 [95% CI 1.98;4.56], $p=5.8\times10^{-7}$). Among DCM G+, 25 individuals (3.1%, genes: 8 *MYH7*, 8 *TTN*, 2 *BAG3*, 2 *DSP*, 2 *FLNC*, 1 *DES*, 1 *SCN5A* and 1 *TNNT2*) were P+. Within HCM G+, 32 individuals (4.0%, genes: 20 *MYBPC3*, 10 *MYH7*, 1 *TNNI3* and 1 *TNNT2*) were P+. For ARVC G+, 4 individuals (1.2%, genes: 2 *DSP*, 1 *DES* and 1 *PKP2*) were P+, being comparable to G- controls (87 subjects, 0.8%).

Ventricular arrhythmias occurred more often in G+ compared to G-, reaching statistical significance for ARVC (OR 6.20 [95% CI 2.30;14.38], $p=3.3\times10^{-4}$) and DCM (OR 4.97 [95% CI 2.39;9.75], $p=1.9\times10^{-5}$). Atrial arrhythmias were more prevalent among DCM G+ (OR 2.27 [95% CI 1.52;3.31], $p=8.2\times10^{-5}$). Finally, all-cause mortality (OR 1.39 [95% CI 1.02;1.85], p=0.032) and death due to a cardiovascular cause were more prevalent in DCM G+ (OR 1.67 [95% CI 1.04;2.59], p=0.030) but did not reach statistical significance for ARVC G+ and HCM G+ ($p\geq0.100$). **Figure I** depicts the overlap in cardiomyopathy, heart failure, ventricular arrhythmia and ischemic heart disease diagnosis. **Figure II** depicts the forest plots when excluding the more prevalent *TNNT2* and *MYBPC3* variants in HCM G+ individuals and **Figure III** shows the association between different outcomes stratified by genes for each cardiomyopathy.

Deep phenotyping of undiagnosed pathogenic variant carriers

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Next, we set out to study early signs of disease in G+ without a cardiomyopathy/heart failure diagnosis (P-) using registered ICD-10 codes, self-reported cardiac symptoms, and abnormal ECG and CMR values.

Diagnosis and symptoms

Ventricular arrhythmias were more prevalent in ARVC G+P- (OR 5.85 [95% CI 1.98;14.40], p=0.001) and DCM G+P- (OR 3.43 [95% CI 1.35;7.68], p=0.005) but not in HCM G+P- (OR 1.01 [95% CI 0.26;2.86], p=1.000) compared to G-P- controls. Also, atrial arrhythmias (OR 2.12 [95% CI 1.36;3.19], $p=7.9\times10^{-4}$) were more frequent in DCM G+P- compared to G-P- controls. Finally, angina pectoris occurred more often in HCM G+P- (OR 1.38 [95% CI 1.01;1.85], p=0.038), but not in ARVC G+P- and DCM G+P- ($p\geq0.117$; **Table VII**).

Electrocardiography

In total, 231 out of 2,207 G+P- and 1,058 out of 9,885 G-P- had various ECG variables available. None of these ECG variables differed significantly between all undiagnosed G+ and control individuals (**Table VIII**).

Cardiac magnetic resonance imaging

CMR data was available in 225 G+P- of the 2,207 unique G+P- individuals: n=33 for ARVC G+P-, n=87 for DCM G+P- and n=130 for HCM G+P-) and 986 of the 9,885 G-P- controls. As shown in **Table IX**, G+P- and G-P- individuals with CMR data available were mostly comparable. Only smoking was more prevalent among DCM G+P- compared to G-P- controls (OR 1.59 [95%CI 1.00; 2.53], p=0.041). Outliers were observed in G-P- controls: 4 individuals with a median age of 64 [60-67] years had a left ventricular ejection fraction (LVEF) below

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

40% and 3 of them were diagnosed with hypertension and 2 with acute myocardial infarction in the past. In addition, 2 individuals with an age of 42 and 52 years old had an RVEF below 40%. They did not suffer from hypertension and did not have any cardiac diagnosis.

As shown in **Figure 5** and **Table VIII**, all RV ($p \geq 0.546$) and LV ($p \geq 0.052$) functional and structural parameters in ARVC G+P- were comparable to G-P- controls. Three ARVC G+P- individuals had an RVEDV corrected for body surface area (RVEDVi) between 100-110 mL/m^2 for males or 90-100 mL/m^2 for females, meeting the minor CMR task force criteria (TFC) if wall motion abnormalities were present, and two ARVC G+P- individuals had an RVEDVi larger than 110 mL/m^2 for males or 100 mL/m^2 for females, meeting the major CMR TFC[10]. In addition, ARVC G+P- had reduced inferior and posterolateral wall thickness compared to controls ($p \leq 0.035$).

Overall, DCM G+P- and G-P- controls had comparable RV functional and structural measures ($p \geq 0.048$). However, DCM G+P- had lower LVEF (57.3% [52.6, 62.8] vs. 59.5% [55.3, 63.5] vs, p=0.009) and less negative LV peak longitudinal strain (-22.3% [-24.6, -19.86] vs. -23.3% [-26.0, -21.4], p=0.009). Although LVEDVi was not significantly increased in DCM G+P-, the LVEDV/RVEDV ratio (0.9 [0.9, 1.0] vs 1.0 [0.9, 1.1], $p=8.2\times10^{-4}$) and LVESVi (30.0 ml/m^2 [25.1, 35.7] vs 31.7 ml/m^2 [26.2, 39.8], p=0.032) were increased. Six individuals had an LVEF below 45%, but none of the individuals met the Henry criteria for DCM (LVEF below 45% and LVEDVi two times the normal SD)[11].

For HCM G+P-, most RV and LV functional and dimension parameters were comparable to G-P- controls ($p \geq 0.051$). Only RVEF was higher than controls (58.4% [54.2, 62.7] vs 59.6% [54.8, 64.0], p=0.025). Importantly, wall thickness was not significantly different between HCM G+P- without a cardiomyopathy/heart failure diagnosis and G-P-

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

(p≥0.160). None of the G+P- individuals met HCM criteria[12] of ≥15 mm wall thickness, but two individuals met the criteria for limited hypertrophy (13-15mm) in the presence of a positive genetic test[12].

Figure IV shows a summary of all the differences tested.

Exclusion of the more prevalent *TNNT2* and *MYBPC3* variants

When excluding the more prevalent *TNNT2* and *MYBPC3* variants in HCM G+P- individuals, the occurrence of ventricular arrhythmias (OR 1.72 [95% CI 0.44;4.89], p=0.306) and atrial arrhythmias (OR 1.43 [95% CI 0.84;2.32], p=0.156) was comparable to G-P- controls. However, the maximum wall thickness (8.47mm [7.59, 9.94] vs. 8.09mm [7.24, 9.01], p=0.008) and basal anterior wall thickness (7.93mm [6.97, 9.11] vs. 7.65mm [6.81, 8.49], p =0.029) were significantly increased in HCM G+P- compared to controls (**Table VIII**). Two individuals had a maximum wall thickness between 13-15mm.

Discussion

In this study we leveraged the largest European population database including WES and phenotype data to evaluate the prevalence and penetrance of previously reported pathogenic and likely pathogenic variants associated with ARVC, DCM and HCM. Our study has several interesting findings. First, we found a prevalence of 1:578, 1:251, and 1:149 for variants previously associated with ARVC, DCM and HCM respectively. Second, 1.2% of ARVC G+, 3.1% of DCM G+ and 2.6% of HCM G+ were diagnosed with a cardiomyopathy or heart failure without previous chronic ischemic heart disease. Finally, 3.2% of the undiagnosed ARVC G+, 1.8% of the undiagnosed DCM G+, 0.5% of the undiagnosed HCM G+ reported

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

ventricular arrhythmias or had CMR abnormalities. These results confirm the low disease penetrance in G+ in the general population.

Prevalence of pathogenic and likely pathogenic variant carriers in the general population

Since rare genetic variants are the major cause of inherited cardiomyopathies , a large dataset is needed to accurately identify the population prevalence of these variants. Prevalence of pathogenic variants in populations has been the focus of several previous studies[4,13-15], however they were mostly limited by the number of included individuals. At time of analysis, we had access to an unprecedented number of 200,643 individuals.

Previously reported prevalence of ARVC G+ in the general population ranges between 1:143 to 1:1,706[13-15]. This variability is likely to be explained by heterogeneity in study populations and definitions of variant pathogenicity. For example, many previous studies did not include all eight curated genes with strong or moderate disease-gene association but also marked other genes (e.g. *TGFB3*) with only limited evidence as associated with ARVC[14,15]. In addition, we included both missense and LoF variants whereas prior studies only included LoF variants.

For DCM, little is known about the prevalence of DCM causing variants in the general population. Studies focusing on truncating *TTN* variants in the general population found a prevalence ranging between 1:33 and 1:526[16,17]. This wide range can partly be explained by the used definition of pathogenicity. Also, disease causing truncating *TTN* variants associated with DCM are known to be highly enriched in the A band. However, recently, truncating variants in the distal I-band region have also been implicated in DCM[18]. When solely focussing on *TTN* variants, we found a prevalence of only 1:735. This differs from the previous studies, probably because not all *TTN* variants are reported as pathogenic or likely

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

pathogenic in ClinVar and VKGL. Including all curated DCM-associated genes, we report a prevalence of 1:251.

For HCM, we found a prevalence ranging between 1:250 and 1:149 individuals carrying a pathogenic or likely pathogenic variant, which approaches previous estimates of 1:164[19]. In a recent study, including the UKB population, a prevalence of 1:407 was reported[20]. They included 8 sarcomere-encoding genes described to be associated with HCM (*ACTC1, MYBPC3*, *MYH7*, *MYL2*, *MYL3*, *TNNI3*, *TNNT2* and *TPM1*) and variants that were described as pathogenic or likely pathogenic in ClinVar or annotated as pathogenic or likely pathogenic according to ACMG criteria and filtered variants for an allele frequency of 0.00004. We included additional genes (*CSRP3*, *JPH2* and *TNNC1*) and pathogenic and likely pathogenic variants from the VKGL database and filtered for a minor allele frequency of 0.001. Especially the latter is a driving force behind the higher prevalence in this study. When also using a minor allele frequency (MAF) <0.00004, the prevalence of our study would be 1:475, approaching the prevalence reported by de Marvao *et al*.[20].

Disease expression of pathogenic and likely pathogenic variants in the general population

Most information on disease penetrance in ARVC, DCM or HCM G+ is based on observations in G+ relatives of cardiomyopathy patients. Previous studies have shown that 37% of ARVC G+ relatives[21] and up to 50% of HCM G+ relatives with sarcomeric variants[22] show disease expression during follow-up. Our findings suggest that disease penetrance in the general population is much lower. We found that 1.2% of ARVC G+, 3.1% of DCM G+ and 2.6% of HCM G+ in the UKB were diagnosed with a cardiomyopathy or heart failure, in the absence of chronic ischemic heart disease. Our additional analysis of ventricular function and ECG in undiagnosed G+ subjects also suggests a low disease penetrance. We found significantly

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

worse LVEF and strain parameters in DCM G+P- compared to controls, however none met the diagnostic Henry criteria (LVEF below 45% and LVEDVi two times the normal SD)[11]. Although CMR data was only available in a subgroup of undiagnosed G+ patients, these findings make it unlikely that the low penetrance found in our study arises from missed diagnoses or covert disease in the G+ cohort. Furthermore, none of the G+P- individuals met HCM criteria[12] of ≥15 mm wall thickness, two individuals did meet the criteria for limited hypertrophy (13-15mm) in the presence of a positive genetic test[12]. Interestingly, maximum wall thickness in de Marvao *et al.*[20] was higher compared to ours. Although this can partly be explained by the inclusion of P+ by Marvao *et al*., this may also be explained by differences in wall thickness calculation method. While Marvao *et al.* uses the absolute largest wall thickness value at a single point, we have used the AHA segment with the largest wall thickness (which is an average of all the single points within one AHA segment to reduce random outliers). In ARVC and DCM G+P- we found a low, but significantly higher prevalence of ventricular arrhythmias compared to controls (1.7% vs. 0.3% (OR 5.85 [95% CI 1.98;14.40]) and 1.0% vs. 0.3% (OR 3.43 [95% CI 1.35;7.68)) respectively). In ARVC, electrical abnormalities are known to precede structural abnormalities[23]. Therefore, these findings may suggest early disease penetrance in a small subset of undiagnosed G+ individuals. The discrepancy between the high disease penetrance found in G+ family members and the low penetrance in the G+ general population points towards the interaction of possible other (unidentified) genetic and environmental factors leading to this variation. The median age of our study population was 57 [49-63] years, however inherited cardiomyopathies are generally diagnosed at a younger age. For ARVC, Groeneweg *et al*. showed, in a cohort of 439 index-patients, that the mean age of first disease presentation is 36±14 years. Most of these patients presented with symptoms (95%), of whom 11% with sudden cardiac arrest[21].

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Likewise in DCM, the mean age of presentation is mostly between 30-50 years[24]. Lastly, in HCM a mean age at presentation of 49±16 years was shown in a cohort of 4893 patients by Lorenzini *et al.*[25]. Interestingly, although mortality rates were low, young HCM patients showed a worse prognosis compared to their healthy peers, with 80% of mortality being caused by sudden cardiac death[25]. Therefore, it should be taken into account that younger patients with disease expression are likely underrepresented in our study. This is not only due to higher mortality and morbidity in especially ARVC and HCM, but also because individuals with a diagnosed cardiomyopathy may be less likely to participate in a large-scale biobank study such as the UKB.

Interestingly, the South Asian *MYBPC3* and the *TNNT2* variant, showed a relatively high prevalence in our cohort. In total, 19% of HCM G+ was Asian and most of these individuals carried the c.3628-41_3628-17del variant in the *MYBPC3* gene. Although this variant is indicated as likely pathogenic in ClinVar, a previous study suggests that this variant may be reclassified as benign[26]. In our study, none of these variant carriers were diagnosed with HCM. Four were diagnosed with heart failure of whom one was diagnosed with DCM. This suggests that this variant is associated with heart failure in the setting of multiple forms of cardiomyopathy, and not simply HCM[26]. Secondly, the c.862C>T p.Arg288Cys variant in *TNNT2* was previously found in HCM individuals but is often observed in patients with a mild phenotype or in combination with other variants. These observations suggest that this variant might not be a monogenic cause of severe HCM but acts in concert with other variants[27]. Interestingly, when excluding these variants from our G+P- population, a significantly higher wall thickness is measured compared to controls. These two examples emphasize that when pathogenic or likely pathogenic variants are identified as a secondary

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

finding, other factors, such as the specific variant and the family history are crucial for follow-up decisions.

We also assessed gene-specific associations with the cardiovascular outcomes. *PKP2* variant carriers showed a stronger association with ventricular arrhythmias (OR 11.90 [95% CI 4.38; 27.86], $p = 6.4\times10^{-6}$) compared to heart failure (OR 1.50 [95% CI 0.48; 3.64], p=0.395). This is in concordance with a previous study showing sustained ventricular arrhythmias to be the first clinical presentation in 61% of ARVC patients[21]. During follow-up, sustained arrhythmias occurred in 72% of ARVC patients, highlighting sustained arrhythmias as the most important ARVC disease manifestation. On the contrary, symptomatic heart failure was seen in 13% of ARVC patients[21]. In DCM G+, ventricular arrhythmias were significantly more present compared to G- controls, especially in *TTN* (OR 4.49 [95% CI 1.15; 12.76], p=0.016), *DES* (OR 12.80 [95% CI 1.45; 52.55], p=0.013) and *LMNA* (OR 15.04 [95% CI 1.69; 62.32], p=0.009) variant carriers. A recent meta-analysis assessing predictors for sustained ventricular arrhythmias, showed *PLN* and *LMNA* to be associated with arrhythmogenic outcome[28]. Although we did not have enough power to study *PLN* G+, *LMNA* G+ did show significantly more ventricular arrhythmias compared to G- controls. Furthermore, *BAG3* variant carriers have been associated with significant risk of progressive heart failure[29]. In our study, *BAG3* variant carriers were significantly more often diagnosed with a cardiomyopathy (OR 41.18 [95% CI 4.36; 192.17], p=0.002). Even though more heart failure cases were seen compared to G- controls, this did not reach statistical significance (**Table X**).

Interestingly, self-reported health-related quality of life and psychological well-being of 89 asymptomatic HCM G+ were previously evaluated in a Dutch cohort and found to be at least similar to the general population, which suggests that reporting incidental findings

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

will not harm psychological well-being of G+[30]. However, frequent cardiological examination of G+ and family members turning out to be carriers after cascade screening will put a burden on health care and societal costs[31]. Genetic screening and cardiological examination are necessary in family members of genetic cardiomyopathy patients since disease expression in family members is considerable. Disease expression in the general population on the other hand is low. Therefore, in case of an incidental finding, multiple factors like family history, presence of symptoms, electrical and/or structural abnormalities and gene and variant type should inform follow-up decisions. Further studies on the genotype-phenotype associations and disease penetrance will aid in facilitating these decisions.

Limitations

Several variants are associated with more than one cardiomyopathy. This is mainly due to phenotypic heterogeneity but may also be partly explained by misdiagnosis. Information is submitted to ClinVar by laboratories, not by clinicians. Phenotype description might therefore be less reliable. To avoid selection bias, we included variants associated with multiple cardiomyopathies in both cardiomyopathy categories, possibly leading to increased prevalence estimates. Although the prevalence of cardiomyopathy variants is slightly affected by including or excluding overlapping variants, this did not substantially affect the results and conclusions (**Table X**). Future studies should focus on reaching consensus on variant-phenotype associations for the variants described in multiple cardiomyopathies to avoid variation in prevalence caused by the use of different definitions. Despite recent efforts to harmonize knowledge on genes associated with inherited cardiomyopathies[5-7], and guidelines for variant classification[31], the adjudication of the clinical significance of single variants can still differ between diagnostic laboratories[31], which has led to

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

interpretation differences and difficulties to compare results among studies using different criteria. This highlights the importance of a single set of criteria to ascertain clinical significance of a single variant. Furthermore, not all pathogenic or likely pathogenic variants are reported in these databases, especially family-specific variants and pathogenic variants in non-Caucasian populations are underreported.

Lastly, G+P- and G-P- individuals with CMR data available were age, sex and ethnicity matched and comparable in the presence of cardiovascular risk factors and diseases. Interestingly, outliers in CMR values were also present in G-P- controls, which could be partly explained by the presence of past myocardial infarctions. Therefore, differences in cardiac function and structure between G+P+ and G-P- could be underestimated.

Conclusion

In a cohort of 200,643 individuals with WES and phenotype data we identified a prevalence of pathogenic variants associated with ARVC, DCM and HCM of 1:578, 1:251 and 1:149 respectively. Among the identified G+ individuals, cardiomyopathy, heart failure and ventricular arrhythmias were more common compared to G-. However, overall disease penetrance was low (1.2-3.1%). Therefore, in case of incidental findings, decisions on application of cascade screening and frequency of cardiological examination should be based on multiple factors besides variant and gene type, such as family history and disease expression.

Acknowledgements

This research has been conducted using the UK Biobank Resource under Application Number 24711.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Funding sources

The work was financially supported by the Netherlands Cardiovascular Research Initiative, an initiative supported by the Dutch Heart Foundation (CardioVasculair Onderzoek Nederland (CVON) projects: DOUBLE-DOSE 2020B005 (AB), PREDICT2 2018-30, eDETECT 2015-12 (PvT, AtR and FA) and PREDICT Young Talent Program (AtR)). In addition, this work was supported by the Dutch Heart Foundation (2015T058 (AtR), 2015T041 (AB) and 2019T045 (MvV and JvS)). Furthermore, MB is supported by the Alexandre Suerman Stipend of the UMC Utrecht (2017), AtR by the UMC Utrecht Fellowship Clinical Research Talent and FA by the UCL Hospitals NIHR Biomedical Research Center.

Disclosures

None

Supplemental Material

Supplemental Methods

Tables I-XI

Figures I-IV

References [32–38]

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

References

1. McKenna WJ, Judge DP. Epidemiology of the inherited cardiomyopathies. *Nat Rev Cardiol*. 2021;18:22-36.
2. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. *Nat Rev Cardiol*. 2013;10:531-547.
3. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2011;124:2761-2796.
4. Miller DT, Lee K, Chung WK, Gordon AS, Herman GE, Klein TE, Stewart DR, Amendola LM, Adelman K, Bale SJ, et al. ACMG SF v3. 0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2021;23:1381-1390.
5. James CA, Jongbloed JD, Hershberger RE, Morales A, Judge DP, Syrris P, Pilichou K, Domingo AM, Murray B, Cadrin-Tourigny J, et al. International evidence based reappraisal of genes associated with arrhythmogenic right ventricular cardiomyopathy using the clinical genome resource framework. *Circ Genom Precis Med*. 2021;14:e003273.
6. Jordan E, Peterson L, Ai T, Asatryan B, Bronicki L, Brown E, Celeghin R, Edwards M, Fan J, Ingles J, et al. Evidence-based assessment of genes in dilated cardiomyopathy. *Circ*. 2021;144:7-19.
7. Ingles J, Goldstein J, Thaxton C, Caleshu C, Corty EW, Crowley SB, Dougherty K, Harrison SM, McGlaughon J, Milko LV, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. *Circ Genom Precis Med*. 2019;12:e002460.
8. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, et al. ClinVar: improving access to variant interpretations and supporting evidence. *Nucleic Acids Res*. 2018;46:D1062-D1067.
9. Szustakowski JD, Balasubramanian S, Kvikstad E, Khalid S, Bronson PG, Sasson A, Wong E, Liu D, Wade Davis J, Haefliger C, et al. Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. *Nat Genet*. 2021;53:942-948.
10. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MG, Daubert JP, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. *Circulation*. 2010;121:1533-1541.
11. Henry WL, Gardin J, Ware J. Echocardiographic measurements in normal subjects from infancy to old age. *Circulation*. 1980;62:1054-1061.
12. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2020;76:3022-3055.
13. Carruth ED, Young W, Beer D, James CA, Calkins H, Jing L, Raghunath S, Hartzel DN, Leader JB, Kirchner HL, et al. Prevalence and electronic health record-based

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

phenotype of loss-of-function genetic variants in arrhythmogenic right ventricular cardiomyopathy-associated genes. *Circ Genom Precis Med*. 2019;12:e002579.

14. Haggerty CM, James CA, Calkins H, Tichnell C, Leader JB, Hartzel DN, Nevius CD, Pendergrass SA, Person TN, Schwartz M, et al. Electronic health record phenotype in subjects with genetic variants associated with arrhythmogenic right ventricular cardiomyopathy: a study of 30,716 subjects with exome sequencing. *Genet Med*. 2017;19:1245-1252.
15. Hall CL, Sutanto H, Dalageorgou C, McKenna WJ, Syrris P, Futema M. Frequency of genetic variants associated with arrhythmogenic right ventricular cardiomyopathy in the genome aggregation database. *Eur J Hum Genet*. 2018;26:1312-1318.
16. Akinrinade O, Koskenvuo JW, Alastalo T-P. Prevalence of titin truncating variants in general population. *PloS One*. 2015;10:e0145284.
17. Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, Conner L, DePalma SR, McDonough B, Sparks E, et al. Truncations of titin causing dilated cardiomyopathy. *N Engl J Med*. 2012;366:619-628.
18. Schafer S, De Marvao A, Adami E, Fiedler LR, Ng B, Khin E, Rackham OJ, Van Heesch S, Pua CJ, Kui M, et al. Titin-truncating variants affect heart function in disease cohorts and the general population. *Nat Genet*. 2017;49:46-53.
19. Bick AG, Flannick J, Ito K, Cheng S, Vasan RS, Parfenov MG, Herman DS, DePalma SR, Gupta N, Gabriel SB, et al. Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. *Am J Hum Genet*. 2012;91:513-519.
20. de Marvao A, McGurk KA, Zheng SL, Thanaj M, Bai W, Duan J, Biffi C, Mazzarotto F, Statton B, Dawes TJ, et al. Phenotypic expression and outcomes in individuals with rare genetic variants of hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2021;78:1097-1110.
21. Groeneweg JA, Bhonsale A, James CA, Te Riele AS, Dooijes D, Tichnell C, Murray B, Wiesfeld AC, Sawant AC, Kassamali B, et al. Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members. *Circ Cardiovasc Genet*. 2015;8:437-446.
22. van Velzen HG, Schinkel AF, Baart SJ, Oldenburg RA, Frohn-Mulder IM, van Slegtenhorst MA, Michels M. Outcomes of contemporary family screening in hypertrophic cardiomyopathy. *Circ Genom Precis Med*. 2018;11:e001896.
23. Gomes J, Finlay M, Ahmed AK, Ciaccio EJ, Asimaki A, Saffitz JE, Quarta G, Nobles M, Syrris P, Chaubey S, et al. Electrophysiological abnormalities precede overt structural changes in arrhythmogenic right ventricular cardiomyopathy due to mutations in desmoplakin-A combined murine and human study. *Eur Heart J*. 2012;33:1942-1953.
24. Hershberger RE, Cowan J, Morales A, Siegfried JD. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Circ Heart Fail*. 2009;2:253-261.
25. Lorenzini M, Anastasiou Z, O'Mahony C, Guttman OP, Gimeno JR, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Garcia-Pavia P, et al. Mortality among referral patients with hypertrophic cardiomyopathy vs the general European population. *JAMA Cardiol*. 2020;5:73-80.
26. Harper AR, Bowman M, Hayesmoore JB, Sage H, Salatino S, Blair E, Campbell C, Currie B, Goel A, McGuire K, et al. Reevaluation of the South Asian MYBPC3 Δ25bp

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Intronic Deletion in Hypertrophic Cardiomyopathy. *Circ Genom Precis Med*. 2020;13:e002783.

27. Ripoll-Vera T, Gámez JM, Govea N, Gómez Y, Núñez J, Socías L, Escandell Á, Rosell J. Clinical and prognostic profiles of cardiomyopathies caused by mutations in the troponin T gene. *Rev Esp Card* . 2016;69:149-158.

28. Kayvanpour E, Sedaghat-Hamedani F, Amr A, Lai A, Haas J, Holzer DB, Frese KS, Keller A, Jensen K, Katus HA, et al. Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals. *Clin Res Cardiol*. 2017;106:127-139.

29. Domínguez F, Cuenca S, Bilińska Z, Toro R, Villard E, Barriales-Villa R, Ochoa JP, Asselbergs F, Sammani A, Franaszczyk M, et al. Dilated cardiomyopathy due to BLC2-associated athanogene 3 (BAG3) mutations. *J Am Coll of Cardiol*. 2018;72:2471-2481.

30. Christiaans I, Van Langen IM, Birnie E, Bonsel GJ, Wilde AA, Smets EM. Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study. *Am J M Genet*. 2009;149:602-612.

31. Fontes Marx M, Ataguba JE, Vries Jd, Wonkam A. Systematic Review of the Economic Evaluation of Returning Incidental Findings in Genomic Research. *Public Health Front*. 2021;9:873.

32. Strande NT, Riggs ER, Buchanan AH, Ceyhan-Birsoy O, DiStefano M, Dwight SS, Goldstein J, Ghosh R, Seifert BA, Sneddon TP, et al. Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the clinical genome resource. *Am J Hum Genet*. 2017;100:895-906.

33. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17:405-423.

34. Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA, Shendure J. Exome sequencing as a tool for Mendelian disease gene discovery. *Nat Rev Genet*. 2011;12:745-755.

35. Petersen SE, Matthews PM, Francis JM, Robson MD, Zemrak F, Boubertakh R, Young AA, Hudson S, Weale P, Garratt S, et al. UK Biobank's cardiovascular magnetic resonance protocol. *J Cardiovasc Magn Reson*. 2015;18:1-7.

36. Ruijsink B, Puyol-Antón E, Oksuz I, Sinclair M, Bai W, Schnabel JA, Razavi R, King AP. Fully automated, quality-controlled cardiac analysis from CMR: validation and large-scale application to characterize cardiac function. JACC *Cardiovasc Imaging*. 2020;13:684-695.

37. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. *Circulation*. 2002;105:539-542.

38. R Core Team. R: A language and environment for statistical computing: Vienna, Austria: R Foundation for Statistical Computing; 2020.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Tables

Table 1: Baseline characteristics of variant carriers and controls

	ARVC G+ n=347	**DCM G+** n=800	**HCM G+** n=1,346	**Controls G-** n=9,972
Demographics				
Female (%)	187 (54)	450 (56)	720 (54)	5,436 (55)
Age, years	57 [50- 64]	58 [51-64]	56 [49-63]	57 [49- 63]
Ethnicity (%)				
White	311 (90)	760 (96)	1,001 (75)	8,288 (84)
Asian	10 (3)	8 (1)	251 (19)	1,076 (11)
Black	7 (2)	12 (2)	22 (2)	164 (2)
Other	17 (5)	15 (2)	55 (4)	348 (4)
Cardiovascular risk factors				
BMI, kg/m^2	26 [24-30]	27 [24-30]	27 [24-30]	27 [24-30]
Diabetes (%)	35 (10)	62 (8)	154 (11)*	914 (9)
Hypertension (%)	116 (33)	287 (36)	475 (35)	3,420 (34)
Hypercholesterolemia (%)	86 (25)	211 (26)	369 (27)*	2,416 (24)
Ever Smoked (%)	161 (46)	371 (46)*	543 (40)	4,132 (41)
MET minutes per week, ml/kg/min	2,001 [923-3,551]	1,695 [784-3,536]	1,762 [848-3,426]	1,773 [810-3,453]
Family heart disease (%)	179 (52)*	380 (48)	623 (46)	4,458 (45)
Cardiac disease/outcomes				
Cardiomyopathy (%)	3 (0.9)	22 (3)**	27 (2)**	37 (0.4)
DCM (%)	2 (0.6)	9 (1)**	1 (0.1)	14 (0.1)
HCM (%)	1 (0.3)	7 (1)**	20 (2)**	8 (0.1)
Heart failure (%)	9 (3)	36 (5)**	33 (3)	182 (2)
Ventricular arrhythmias (%)	7 (2)**	13 (2)**	8 (1)	33 (0.3)

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Atrial arrhythmias (%)	7 (2)	34 (4)**	32 (2)	191 (2)
Chronic ischemic heart disease (%)	35 (10)	73 (9)	93 (7)	725 (7)
Acute myocardial infarction (%)	15 (4)	27 (3)	36 (3)	298 (3)
Cardiac arrest (%)	0 (0)	6 (1)	5 (0.4)	34 (0.3)
Cardiovascular death (%)	11 (3)	24 (3)*	18 (1)	181 (2)
All cause mortality (%)	19 (6)	56 (7)*	62 (5)	513 (5)
Cardiac symptoms				
Cardiac problem	3 (1)	3 (0.4)	5 (0.4)	41 (0.4)
Angina pectoris	16 (5)	30 (4)	56 (4)*	312 (3)

Number (percentages) are given or median [IQR]. * p=0.001-0.05 and ** p <0.001 difference compared to the control group. A more extensive overview of the baseline characteristics are given in **Table III.** Individuals with a variant in *PLN*, *DES* and *DSP* variant were included in both ARVC and DCM. Individuals with a variant in *MYH7*, *ACTC*, *JPH*, *TNNC1*, *TNNI3*, *TNNT2*, *TPM* were included in both DCM and HCM.
Abbreviations: ARVC= arrhythmogenic right ventricular cardiomyopathy; DCM= dilated cardiomyopathy; HCM= hypertrophic cardiomyopathy; BMI= body mass index; MET= metabolic equivalent of task.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Figures

Figure 1: Included curated genes per cardiomyopathy

The Venn diagram of curated genes included in this study shows the overlap in genes per cardiomyopathy. Unless otherwise indicated, pathogenicity of genes are classified as definitive. If a superscript S or M is given, genes are classified as having a strong or moderate pathogenicity respectively. In the overlapping circles, yellow, black and red colors refer to ARVC, DCM, and HCM respectively. ***Table I*** *gives an overview of the included genes and pathogenicity classification per gene and abbreviation per gene.*
Abbreviations: ARVC= arrhythmogenic right ventricular cardiomyopathy; DCM= dilated cardiomyopathy; HCM= hypertrophic cardiomyopathy.

Figure 2: Flowchart inclusion of variants

Flowchart depicting the inclusion of pathogenic and likely pathogenic variants associated with arrhythmogenic cardiomyopathy, dilated cardiomyopathy and hypertrophic cardiomyopathy from the ClinVar[8] and VKGL database.
Abbreviations: ARVC= arrhythmogenic right ventricular cardiomyopathy; DCM= dilated cardiomyopathy; HCM= hypertrophic cardiomyopathy; VKGL= Vereniging Klinische Genetische Laboratoriumdiagnostiek.

Figure 3: Distribution of genes per cardiomyopathy

Piecharts with the distribution of curated genes for A) arrhythmogenic right ventricular cardiomyopathy (ARVC); B) dilated cardiomyopathy (DCM); C) hypertrophic cardiomyopathy (HCM).
Abbreviations of the different genes are given in ***Table III***
Abbreviations: G+= pathogenic variant carrier.

Figure 4: Forest plot cardiac outcomes stratified per inherited cardiomyopathy

Odds ratios and 95% confidence interval are given for the associations between cardiac outcomes and ARVC, DCM, or HCM pathogenic variant carriers.
Abbreviations: ARVC= arrhythmogenic right ventricular cardiomyopathy; DCM= dilated cardiomyopathy; G+= pathogenic variant carrier; HCM= hypertrophic cardiomyopathy.

Figure 5: CMR parameters stratified per inherited cardiomyopathy

Boxplots of CMR parameters showing the summary statistics of CMR parameters stratified by controls and individuals with a pathogenic variant associated with ARVC, DCM, or HCM. Displayed summary statistics include the median, first and third quartile (lower and upper box edges), and the whiskers represent values within 1.5 times the interquartile range from the box edges.
Abbreviations: ARVC= arrhythmogenic right ventricular cardiomyopathy; DCM= dilated cardiomyopathy; EDVi= body surface area corrected end-diastolic volume; EF= ejection fraction; G+= pathogenic variant carrier; HCM= hypertrophic cardiomyopathy; LV= left ventricular; RV= right ventricular.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .



medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



medRxiv preprint doi: https://doi.org/10.1101/2022.01.06.22268837; this version posted July 12, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .